| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Hae-Sim Park | Q12597311 |
| Han Ki Park | Q88064242 | ||
| P2093 | author name string | Youngwoo Choi | |
| Chang-Gyu Jung | |||
| P2860 | cites work | Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics | Q77950275 |
| Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses | Q78247441 | ||
| Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma | Q24564777 | ||
| Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes | Q24633568 | ||
| Update on the Management of Aspirin-Exacerbated Respiratory Disease | Q26749097 | ||
| Using Periostin as a Biomarker in the Treatment of Asthma | Q28067637 | ||
| Eicosanoid Mediators in the Airway Inflammation of Asthmatic Patients: What is New? | Q28079269 | ||
| RANTES, eotaxin and eotaxin‐2 expression and production in patients with aspirin triad | Q28166107 | ||
| Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase | Q28166997 | ||
| HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population | Q28167635 | ||
| Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach | Q28171243 | ||
| Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis | Q28176722 | ||
| Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics | Q28181347 | ||
| Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma | Q28191455 | ||
| Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma | Q28193250 | ||
| A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma | Q28193908 | ||
| The involvement of adhesion molecules and lipid mediators in the adhesion of human platelets to eosinophils | Q28194290 | ||
| A controlled study of 9α,11β-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge | Q28195706 | ||
| Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males | Q28196697 | ||
| A polymorphism of MS4A2 (- 109T > C) encoding the beta-chain of the high-affinity immunoglobulin E receptor (FcepsilonR1beta) is associated with a susceptibility to aspirin-intolerant asthma | Q28199476 | ||
| Association between polymorphisms in prostanoid receptor genes and aspirin-intolerant asthma | Q28210399 | ||
| The HLA-DPB1*0301 marker might predict the requirement for leukotriene receptor antagonist in patients with aspirin-intolerant asthma | Q28213777 | ||
| Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity | Q28217507 | ||
| Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease | Q28260095 | ||
| Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease | Q30410446 | ||
| Asthma outcomes: biomarkers | Q30425168 | ||
| Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma | Q33921113 | ||
| Intolerance to aspirin. Clinical studies and consideration of its pathogenesis | Q34236999 | ||
| Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease | Q50439928 | ||
| Urinary leukotriene E4 and 11-dehydrothromboxane B2 in patients with aspirin-sensitive asthma. | Q50950983 | ||
| Impaired sphingolipid synthesis in the respiratory tract induces airway hyperreactivity. | Q50969955 | ||
| Metabolomic analysis identifies potential diagnostic biomarkers for aspirin-exacerbated respiratory disease. | Q51469727 | ||
| Aspirin-Exacerbated Respiratory Disease--New Prime Suspects. | Q51550145 | ||
| Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity. | Q51703960 | ||
| Association of serum periostin with aspirin-exacerbated respiratory disease. | Q51709821 | ||
| Clinical course of patients with aspirin-exacerbated respiratory disease: can we predict the prognosis? | Q53291503 | ||
| Genome-wide association study of aspirin-exacerbated respiratory disease in a Korean population. | Q53352652 | ||
| The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma | Q57892223 | ||
| Immunohistochemical Characterization of Cellular Infiltrate in Nasal Polyp from Aspirin-Sensitive Asthmatic Patients | Q58192622 | ||
| Reduced expression of COXs and production of prostaglandin E2 in patients with nasal polyps with or without aspirin-intolerant asthma | Q62520456 | ||
| Urinary Excretion of Leukotriene E4and 11-dehydro-Thromboxane B2in Response to Bronchial Provocations with Allergen, Aspirin, Leukotriene D4, and Histamine in Asthmatics | Q67491772 | ||
| Urinary Leukotriene E4Concentrations Increase after Aspirin Challenge in Aspirin-sensitive Asthmatic Subjects | Q67915846 | ||
| Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma | Q70906164 | ||
| Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma | Q72352958 | ||
| The relationship between airways inflammation and asthma severity | Q73321264 | ||
| Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes | Q73405806 | ||
| GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP) | Q77371567 | ||
| The role of periostin in tissue remodeling across health and disease. | Q34379268 | ||
| Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature | Q34441715 | ||
| The SNP rs3128965 of HLA-DPB1 as a genetic marker of the AERD phenotype | Q34764489 | ||
| Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease | Q34832426 | ||
| Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease | Q34892917 | ||
| Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma | Q35536702 | ||
| Association between severity of asthma and degree of chronic rhinosinusitis | Q36077690 | ||
| Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway | Q36119388 | ||
| Platelet-lymphocyte cross-talk | Q37058252 | ||
| Exploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease. | Q37405580 | ||
| Diagnostic Utility of Urinary LTE4 in Asthma, Allergic Rhinitis, Chronic Rhinosinusitis, Nasal Polyps, and Aspirin Sensitivity | Q37406340 | ||
| Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome | Q37833778 | ||
| Asthma phenotypes: the evolution from clinical to molecular approaches | Q38007831 | ||
| Untangling asthma phenotypes and endotypes | Q38010795 | ||
| Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites | Q38013046 | ||
| Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma | Q38308690 | ||
| Local immunoglobulin e in the nasal mucosa: clinical implications | Q38370137 | ||
| Aspirin-exacerbated respiratory disease: an update | Q38960871 | ||
| Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis | Q38973949 | ||
| Lipid Mediators in Aspirin-Exacerbated Respiratory Disease | Q38973968 | ||
| The -444A/C polymorphism in the LTC4S gene and the risk of asthma: a meta-analysis | Q39570759 | ||
| Aspirin or Nonsteroidal Anti-inflammatory Drug-Exacerbated Chronic Rhinosinusitis | Q40620143 | ||
| Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease | Q41146048 | ||
| Association of PTGER gene family polymorphisms with aspirin intolerant asthma in Korean asthmatics | Q43001991 | ||
| Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge | Q43069043 | ||
| Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers | Q43123009 | ||
| Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. | Q44247874 | ||
| Etiology of nasal polyps associated with aspirin-sensitive asthma | Q45412042 | ||
| Systemic administration of sphingosine-1-phosphate increases bronchial hyperresponsiveness in the mouse. | Q45952428 | ||
| Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis. | Q45986027 | ||
| Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. | Q46403708 | ||
| Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma | Q46506445 | ||
| Association of four-locus gene interaction with aspirin-intolerant asthma in Korean asthmatics | Q46671450 | ||
| Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study | Q46850970 | ||
| Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease | Q47958695 | ||
| Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease | Q49093882 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | non-steroidal anti-inflammatory drug | Q188724 |
| anti-inflammatory agent | Q581996 | ||
| biomarker | Q864574 | ||
| respiratory disease | Q3286546 | ||
| P304 | page(s) | 8160148 | |
| P577 | publication date | 2017-08-09 | |
| P1433 | published in | Mediators of Inflammation | Q2144494 |
| P1476 | title | Potential Biomarkers for NSAID-Exacerbated Respiratory Disease | |
| P478 | volume | 2017 |
| Q47678797 | An update on the management of aspirin-exacerbated respiratory disease | cites work | P2860 |
Search more.